Monday June 26th 2017

Archive for November, 2016

Researchers use microbubbles and ultrasound to transport drugs across blood–brain barrier

Researchers use microbubbles and ultrasound to transport drugs across blood–brain barrier

The impassable blood-brain barrier prevents microorganisms from entering our brain, however it also blocks medicines that could help treat Parkinson's, Alzheimer's and other neurodegenerative diseases. [Read More]

Higher Vitamin D Level in Newborns Associated with Reduced MS Risk Later (FREE)

Higher Vitamin D Level in Newborns Associated with Reduced MS Risk Later (FREE)

By Robert T. Naismith, MD Dr. Naismith is an associate editor with NEJM Journal Watch Neurology, from which this story was adapted. Full coverage is available to subscribers at the link below.Higher serum vitamin D in the neonatal period is associated with reduced risk for [Read More]

New Study Finds Low Vitamin D Levels in Newborns Linked to Increased Risk for MS Later in Life

New Study Finds Low Vitamin D Levels in Newborns Linked to Increased Risk for MS Later in Life

/About-the-Society/News/New-Study-Finds-Low-Vitamin-D-Levels-in-Newborns-L [Read More]

 Page 1 of 16  1  2  3  4  5 » ...  Last » 

Latest Topics

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug

Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]